features: Ovarian Cancer

First-line maintenance with olaparib monotherapy and in combination bevacizumab increases survival in advanced ovarian cancer

Over 75% of patients with ovarian cancer are diagnosed at an advanced stage, as early-stage disease is usually asymptomatic.1,2 The…

Sig3 mutation and immune score determine responses to combination PARP and PD-1 inhibition in ovarian cancer

Immune checkpoint inhibitors have shown promising therapeutic outcomes in many types of cancer, but ovarian cancer has been an exception….

NHS approval for ovarian cancer drug, olaparib

Olaparib, a maintenance therapy for ovarian cancer, may prolong the benefit of initial treatment in BRCA1/2 mutated ovarian cancer patients…